Skip to main content
micro-community-banner
 
  • Saved

made a Post

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer

The rising cost of cancer drug therapy threatens the long-term sustainability of Taiwan National Health Insurance. Cost savings can be achieved through various strategies, e.g., using smaller vial sizes, sharing ..... see more

Source : https://www.thebreastonline.com/article/S0960-9776(22)00124-2/fulltext


Conclusion: The trastuzumab biosimilar combination regimen is cost-effective and offers significant drug cost savings in Taiwan.

  • Saved

made a Post

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials - PubMed

Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35818669/


Conclusions: Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of biosimilar insulins compared with that of reference insulins, healthcare professionals and insulin users must gain further awareness and...

  • Saved

made a Post

Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials

Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs. It was developed by Pfizer, USA. It is a ..... see more

Source : https://www.eurekaselect.com/article/122387


Relevance: Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

  • Saved

made a Post

Biosimilars Use In Medicine For Inflammatory Diseases

Biosimilars are biological agents that are highly analogous to their reference products currently approved and licensed by the U.S. Food and Drug Administration (FDA). Biosimilars possess no differences in their ..... see more

Source : https://www.ncbi.nlm.nih.gov/books/NBK574572/


Conclusion: Clinicians can expand their knowledge base and awareness of advances in biosimilars and their use in specialty practices from their respective specialty associations. Additional information can also be attained from the FDA website. The cost-saving potential of biosimilars should be taken into account and analyzed for the best...

  • Saved

made a Post

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer - PubMed

doi: 10.1016/j.breast.2022.07.007. Online ahead of print. 1 Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan. Electronic address: [email protected] 2 Department of Surgery, An-Nan Hospital, China ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35870421/


Conclusion: The trastuzumab biosimilar combination regimen is cost-effective and offers significant drug cost savings in Taiwan.

  • Saved

made a Post

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies - BioDrugs

Background Multiple switches (transitions) between biosimilars of the same reference biologic are now a reality, and they are expected to become more common in the future as more biosimilars enter ..... see more

Source : https://link.springer.com/article/10.1007/s40259-022-00546-6


Conclusion: Within the limitations of this systematic review, available data suggests that biosimilar-to-biosimilar switching is a safe and effective clinical practice, although it is not covered by current health authority regulations or guidance. No reduction in effectiveness or increase in adverse events was detected in...

  • Saved

made a Post

Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis

Background: Bevacizumab biosimilars are slowly making their way into cancer treatment, but the data on their efficacy and safety in cancer patients are still poor. see more

Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.880090/full


Conclusion: In patients with advanced NSCLC or metastatic CRC, the efficacy and safety of bevacizumab biosimilars were found to be comparable with those of reference biologics and each other.

  • Saved

made a Post

Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons - PubMed

The confirmation of the HER2-low paradigm is expected to have a major impact in breast oncology. About half of all breast cancers harbor HER2-low expression, which can be targeted with ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35856622/


Conclusion/Relevance: In this article, we recapitulate the current knowledge on HER2-low breast cancer, discussing whether it should be considered a distinct subtype, how it should be implemented in the clinic, and how its definition may evolve in the coming years with the evolution of our clinical and translational knowledge.

  • Saved

made a Post

Case Report: Initial Treatment Adjustments and Complications in Ovarian Cancer Patient With Inborn Error of Immunity - PubMed

Our patient with ovarian cancer and IEI required modified treatment and prevention of complications. In cases of IEI, optimal chemotherapy should be titrated to minimize immunosuppression yet treat cancer aggressively ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35847860/


Conclusions: Our patient with ovarian cancer and IEI required modified treatment and prevention of complications. In cases of IEI, optimal chemotherapy should be titrated to minimize immunosuppression yet treat cancer aggressively while decreasing the risk of infection with prophylactic antibiotics and prolonged post-treatment surveillance,...

  • Saved

made a Post

Projected US Savings From Biosimilars, 2021-2025

Objectives: Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain. We projected ..... see more

Source : https://www.ajmc.com/view/projected-us-savings-from-biosimilars-2021-2025


Conclusions: Biosimilar savings from 2021 to 2025 were $38.4 billion under our main assumptions. Greater savings may be feasible if managed care and other settings increase biosimilar utilization and promote competition.

  • Saved

made a Post

In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2 - PubMed

Breast cancer is a type of cancer with the highest prevalence worldwide. Almost 10-30% of breast cancer cases are diagnosed as positive for HER2 (human epidermal growth factor receptor 2). ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35808792/



Conclusion: Thus, a cominbation of α-mangostin and chitosan conjugated to a trastuzumab formulation was predicted can increase the effectiveness of breast cancer therapy at a relatively small particle size but with the consequence of decreasing atomic contact energy.

  • Saved

made a Post

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland - BioDrugs

Background Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to ..... see more

Source : https://link.springer.com/article/10.1007/s40259-022-00540-y


Conclusions: Changes in pricing policy and the public reimbursement scheme related to the market entry of biosimilars were the main reasons for the decrease in the prices of reference products. Therefore, biosimilars did not generate genuine price competition between biological products. In many of the drug groups examined, the market shares...

  • Saved

made a Post

Immunological Landscape of HER-2 Positive Breast Cancer - PubMed

Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35804943/


Relevance: This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.

  • Saved

made a Post

Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems

The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains inconsistent ..... see more

Source : https://www.ajmc.com/view/uptake-of-oncology-biosimilars-managed-care-strategies-to-improve-value-based-care-systems


Conclusion: Real-world switch studies in oncology biosimilars that have demonstrated bioequivalence provide basis to support efficacy and safety to transition to a biosimilar product. Incorporating oncology biosimilars into treatment pathways will be an important next step in providing value-based care to patients with cancer.

  • Saved

made a Post

Discovery of Novel Polyamide-Pyrrolobenzodiazepine Hybrids for Antibody-Drug Conjugates - PubMed

Pyrrolobenzodiazepine (PBD) dimers are well-known highly potent antibody drug conjugate (ADC) payloads. The corresponding PBD monomers, in contrast, have received much less attention from the ADC community. We prepared several ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35788036/


Relevance: “Pyrrolobenzodiazepine (PBD) dimers are well-known highly potent antibody drug conjugate (ADC) payloads. The corresponding PBD monomers, in contrast, have received much less attention from the ADC community …. Several peptide-linked variants of the lead compound were prepared and conjugated to trastuzumab to afford ADCs with...

  • Saved

made a Post

Drugs and Lactation Database (LactMed) [Internet].

Filgrastim in the pharmaceutical name for granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim is the long-acting form of filgrastim. The excretion of exogenous G-CSF into breastmilk or its effects on breastfed infants ..... see more

Source : https://www.ncbi.nlm.nih.gov/books/NBK501373/


Conclusion: Published information on the effects of filgrastim in breastmilk was not found as of the revision date. However, oral filgrastim 20 mcg daily for 5 days has been given to preterm infants with stage I necrotizing enterocolitis (NEC). Filgrastim appeared to halt progression to more severe stages of NEC in this small study.

  • Saved

made a Post

[Review] Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective

The Lancet Oncology, The Lancet (Reed Elsevier) In a multiday conference, a panel of Latin American experts in biological cancer therapies and health economics were provided with questions to address ..... see more

Source : https://www.lifescience.net/entries/527407/review-streamlining-breast-cancer-and-colorectal-c/


Relevance: In a multiday conference, a panel of Latin American experts in biological cancer therapies and health economics were provided with questions to address the barriers restricting access to biosimilars in Latin America, specifically for patients with breast cancer and colorectal cancer, for whom biosimilars can be a path forward to...

  • Saved

made a Post

Pharmacists' Perspectives of Biosimilars: A Systematic Review - BioDrugs

Background and Objective While biosimilars are less expensive than their originator biologics, various factors are known to impede their uptake in clinical practice including concerns regarding their interchangeability, efficacy, and ..... see more

Source : https://link.springer.com/article/10.1007/s40259-022-00541-x


Conclusions: Pharmacists’ knowledge and perception about biosimilars varied and were limited, especially about interchangeability and substitution, efficacy, safety, and indication extrapolation. A better understanding of biosimilars amongst pharmacists could help them to encourage prescribers’ acceptance of biosimilars.

  • Saved

made a Post

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study - PubMed

Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35758368/


Relevance: Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials have examined the efficacy of trastuzumab in this setting. This prospective observational study aimed to...

  • Saved

made a Post

Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice - PubMed

Head-to-head clinical trials are critically important to advance the field of IBD. Comparative efficacy trials are slow and expensive to conduct, may not be broadly generalizable, and are not powered ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35762693/


Summary: Head-to-head clinical trials are critically important to advance the field of IBD. Comparative efficacy trials are slow and expensive to conduct, may not be broadly generalizable, and are not powered for safety events or other relevant outcomes. Alternative approaches to comparative effectiveness such as network meta-analysis and well...